Renal Tumor Complexity — Nephron-Sparing Surgery Planning
PADUA Parameters
Awaiting Selections
Complete all 6 CT-based anatomical parameters to calculate the PADUA score.
Guidelines & Evidence
Verified
Last Review: 2026
When to Use
When to Use the PADUA Score
Preoperative planning for partial nephrectomy (open, laparoscopic, or robotic) for cT1a (≤ 4 cm) and cT1b (4–7 cm) renal tumors
Predicting surgical difficulty (operative time, estimated blood loss, warm ischemia time, clamping technique, need for collecting system repair)
Estimating risk of postoperative complications (Clavien grade ≥ 3: urinary fistula, bleeding requiring transfusion, acute kidney injury, prolonged hospital stay)
Deciding between partial nephrectomy vs radical nephrectomy (high complexity PADUA ≥ 10 may favor radical nephrectomy in elderly or comorbid patients)
Selecting surgical approach: (1) Low complexity (6–7): suitable for laparoscopic or robotic partial nephrectomy by intermediate-volume surgeons; (2) Moderate (8–9): robotic partial preferred over laparoscopic (lower warm ischemia time, fewer complications); (3) High (10–14): refer to high-volume robotic surgeon, consider open partial nephrectomy if robotic not available, or radical nephrectomy if patient frail
Patient counseling: explaining risk of complications and probability of renal function preservation (PADUA high predicts postoperative eGFR drop > 30% in 20–30% of patients)
Clinical trials of partial nephrectomy: stratifying by PADUA score ensures comparability of tumor complexity across study arms
Quality assessment of partial nephrectomy outcomes: case-mix adjustment using PADUA score (hospitals with more high-complexity tumors should have higher complication rates)
PADUA vs R.E.N.A.L. Nephrometry Score — Comprehensive Comparison
| Feature | PADUA Score (2009, European) | R.E.N.A.L Nephrometry Score (2009, US) | Key Difference | Which to Use When |
|---|---|---|---|---|
| Purpose | Predict surgical difficulty, complication risk, and renal function preservation after partial nephrectomy | Same (surgical complexity, ischemia time, complication risk, conversion to radical) | Similar purposes; both correlate strongly (r = 0.85–0.90) | Use both for research (consensus). For clinical, use either (both validated). PADUA simpler (6 variables vs 5 for R.E.N.A.L.) but R.E.N.A.L. more widely known in US. |
| Variables (6 or 5) | 1. Longitudinal location (polar vs interpolar) 2. Exophytic rate (≥50% vs <50%) 3. Renal rim involvement (lateral vs medial) 4. Tumor size (≤4, 4.1-6, >6 cm) 5. Collecting system involvement (no vs yes) 6. Renal sinus involvement (no vs yes) | 1. R (Radius) — tumor size (≤4, 4.1-7, >7 cm) 2. E (Exophytic) — ≥50%, <50%, endophytic 3. N (Nearness) — distance to collecting system/sinus (≥7, 4-6, <4 mm) 4. A (Anterior/Posterior) — a/p descriptor 5. L (Location) — polar vs interpolar (h) — hilar (optional) | PADUA includes renal rim (medial/lateral) — predicts collecting system entry; R.E.N.A.L. includes nearness in mm (more granular). R.E.N.A.L. includes anterior/posterior (important for approach, not in PADUA). | R.E.N.A.L. better for tumor location (describes anterior/posterior, helpful for robotic port placement). PADUA simpler for quick calculation. Both accepted by EAU and AUA guidelines. |
| Score range | 6–14 (higher = more complex) | 4–12 (higher = more complex) | PADUA 14 max vs R.E.N.A.L. 12 max (R.E.N.A.L. excludes A from scoring; A is descriptor only). | Do not directly convert scores; use percentile or complexity groups. |
| Complexity groups | Low (6–7) Moderate (8–9) High (10–14) | Low (4–6) Moderate (7–9) High (10–12) | Distribution similar (low: ~30%, moderate: ~50%, high: ~20% in most cohorts) | Interchangeable for group assignment (low vs moderate vs high). High group (PADUA 10–14, R.E.N.A.L. 10–12) predicts 30–40% complication rate. |
| Correlation with outcomes | Warm ischemia time (r=0.55), operative time (r=0.52), estimated blood loss (r=0.45), Clavien ≥ 3 (OR per 1-point increase = 1.4) | Similar (r=0.50–0.60 for ischemia time, OR 1.3-1.5 for complications) | Equivalent predictive accuracy (AUC 0.70–0.75 for complications, p=NS in head-to-head) | No preference — institutional familiarity. |
| Limitations | Does not include anterior/posterior (laparoscopic/robotic approach planning), no hilar designation (central tumors), coarse size categories (4-6, >6 cm vs R.E.N.A.L. 4-7, >7 cm) | Nearness in mm requires fine CT measurement (more work), no renal rim (medial vs lateral) predicting collecting system entry | PADUA simpler but less granular; R.E.N.A.L. more detailed but more time-consuming | Research: report both. Clinical: use whichever familiar, add anterior/posterior if PADUA. |
What PADUA Does NOT Predict (Limitations)
Tumor histology (benign vs malignant, Fuhrman/WHO grade) — PADUA does not differentiate between oncocytoma (benign) vs clear cell RCC (malignant). Need biopsy or imaging (bosniak classification for cystic, MRI features)
Lymph node metastasis (cN1-2) — PADUA is for primary tumor anatomy only; does not predict nodal involvement (indicated by CT/MRI size > 1 cm short axis, PET-CT for high-risk)
Distant metastasis — PADUA score does not replace staging CT chest/abdomen/pelvis. High PADUA tumor (e.g., 12–14) may be large but still M0; low PADUA (6–7) may still be metastatic (rare for T1a but possible).
Patient-specific surgical risk (comorbidities, ASA score, obesity, prior abdominal surgery, coagulopathy) — PADUA is tumor-specific. Combine with Charlson Comorbidity Index, BMI, and surgeon experience for individual risk prediction.
Renal function preservation (ischemia-reperfusion injury) — PADUA predicts baseline complexity, but ultimate renal function depends on (a) preoperative GFR, (b) parenchymal volume saved (surgeon skill), (c) ischemic time (clamping strategy: off-clamp vs on-clamp, warm vs cold), (d) baseline CKD stage.
Probability of positive surgical margins — PADUA moderately correlates (r=0.40) but strong surgeon dependence (high-volume center 1-3% positive margin rate even for PADUA 10–14; low-volume center 10-20%).
Last Comprehensive Review: 2026